FLEX NEOADJUVANT PUBLICATIONS & ABSTRACTS
Clinical evidence from FLEX
Evidence / Neoadjuvant / FLEX
MammaPrint + BluePrint predict pCR after NCT-FLEX, O’Shaughnessy et al., SABCS 2023 Abstract
SABCS 2023, PO5-15-04 Authors: O'Shaughnessy et al.
Read MoreRacial Disparities in HR+HER2- ESBC, Reid et al., SABCS 2023 Abstract
SABCS 2023, PO1-28-01 Authors: Sonya Reid et al.
Read MoreRacial Disparities in Latin American Patients-FLEX, Mazo Canola et al., SABCS 2023 Abstract
SABCS 2023, PS18-04 Authors: Marcela Mazo Canola et al.
Read MoreResponse Predictive Subtypes in Lobular Tumors-FLEX, Mukhtar et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-03 Authors: Mukhtar et al.
Read MoreImPrint immune signature in 10,000 early stage breast cancer patients from FLEX Study
SABCS 2022, Poster ID: PD9-08 Authors: Brufsky et al.
Read MoreImpact of Neoadjuvant Endocrine Therapy on Tumor Transcriptome in Patients With Early-Stage Breast Cancer From the FLEX Trial
PUBLICATION: San Antonio Breast Cancer Symposium 2022 TITLE: Impact of neoadjuvant endocrine therapy on tumor transcriptome in patients with early-stage breast cancer from the FLEX trial AUTHORS: Mehran Habibi1, Danijela Jelovac1, Rima Couzi1, Cesar Agusto Santa-Maria1, Catherine Klein1, Marissa White1, Nivali Naik1, Jennifer Wei2, Yen Huynh2, Architha Ellappalayam3, Lisa Read More
Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint
PUBLICATION: ASCO 2021 ย Authors Joyce OโShaughnessy1, Virginia G. Kaklamani2, Yuan Yuan3, Julie Barone4, Sami Diab5, Jennifer A. Crozier6, Pat W. Whitworth7, Karen L. Tedesco8, Robert Maganini9, Rakhshanda Layeequr Rahman10, Carlos A. Encarnacion11, Josien Haan12, Amy M. Truitt12, Andrea Menicucci12, William Audeh12, FLEX Investigatorsโ Group13 Background The 80-gene signature Read More
